Main Management ETF Advisors LLC Buys New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)

Main Management ETF Advisors LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,880 shares of the company’s stock, valued at approximately $706,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Summit Trail Advisors LLC bought a new position in shares of Krystal Biotech in the third quarter valued at $1,893,000. Swiss National Bank boosted its position in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. boosted its position in Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after purchasing an additional 6,363 shares during the period. Shaker Investments LLC OH bought a new position in Krystal Biotech during the third quarter worth $532,000. Finally, Citigroup Inc. boosted its position in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after purchasing an additional 13,874 shares during the period. 86.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Evercore ISI lifted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Citigroup lifted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $202.29.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is owned by insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $185.25 on Friday. The firm has a 50-day moving average of $181.27 and a 200-day moving average of $184.52. The stock has a market cap of $5.33 billion, a PE ratio of 104.66 and a beta of 0.80. Krystal Biotech, Inc. has a 52-week low of $101.34 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.67) earnings per share. Equities research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).